Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Cytomx Therapeutics, Inc. (CTMX)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 65,160,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 47,819 75,591 103,916 162,805
Total Sell Value $99,726 $138,068 $174,902 $267,502
Total People Sold 5 5 5 8
Total Sell Transactions 5 10 14 26
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 38
  Page 1 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Belvin Marcia SVP, Chief Scientific Officer   •       –      –    2023-03-22 3 IO $0.00 $0 D/D 0 80,820     -
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2023-03-22 4 A $0.00 $0 D/D 60,000 140,820     -
   Ogden Christopher SVP, Finance and Accounting   •       •      –    2023-03-16 4 S $1.98 $1,021 D/D (516) 37,772     -
   Campoy Carlos Chief Financial Officer   •       •      –    2023-03-16 4 S $1.98 $3,459 D/D (1,748) 38,224     -
   Landau Jeffrey B Chief Financial Officer   •       •      –    2023-03-16 4 S $1.98 $2,923 D/D (1,477) 69,248     -
   Mccarthy Sean A. CEO   •       •      –    2023-03-16 4 S $1.88 $13,391 D/D (7,121) 388,821     -
   Rowland Lloyd A General Counsel   •       •      –    2023-03-16 4 S $1.98 $4,031 D/D (2,037) 71,095     -
   Peterson Amy C. EVP, Chief Development Officer   •       •      –    2023-03-16 4 S $1.98 $8,425 D/D (4,257) 58,433     -
   Landau Jeffrey B Chief Business Officer   •       –      –    2023-02-02 4 A $0.00 $0 D/D 40,000 70,725     -
   Rowland Lloyd A General Counsel   •       –      –    2023-02-02 4 A $0.00 $0 D/D 25,000 73,132     -
   Mccarthy Sean A. CEO   •       •      –    2023-02-02 4 A $0.00 $0 D/D 105,000 395,942     -
   Ogden Christopher SVP, Finance and Accounting   •       –      –    2023-02-02 4 A $0.00 $0 D/D 25,000 38,288     -
   Rowland Lloyd A General Counsel   •       –      –    2022-07-20 4 S $1.42 $7,968 D/D (5,602) 43,689     -
   Campoy Carlos Chief Financial Officer   •       –      –    2022-07-20 4 S $1.42 $5,617 D/D (3,949) 39,972     -
   Landau Jeffrey B Chief Business Officer   •       –      –    2022-07-20 4 S $1.42 $5,982 D/D (4,206) 30,725     -
   Peterson Amy C. EVP, Chief Development Officer   •       –      –    2022-07-20 4 S $1.42 $10,612 D/D (7,463) 62,690     -
   Hannah Alison L. Chief Medical Officer   •       –      –    2022-07-20 4 S $1.42 $7,965 D/D (5,602) 31,898     -
   Mccarthy Sean A. President and CEO   •       •      –    2022-07-20 4 S $1.42 $21,206 D/D (14,911) 290,942     -
   Rowland Lloyd A General Counsel   •       –      –    2022-07-19 4 A $0.00 $0 D/D 15,000 49,291     -
   Campoy Carlos Chief Financial Officer   •       –      –    2022-07-19 4 A $0.00 $0 D/D 15,000 43,921     -
   Landau Jeffrey B Chief Business Officer   •       –      –    2022-07-19 4 A $0.00 $0 D/D 11,250 34,931     -
   Peterson Amy C. EVP, Chief Development Officer   •       –      –    2022-07-19 4 A $0.00 $0 D/D 20,000 70,153     -
   Hannah Alison L. Chief Medical Officer   •       –      –    2022-07-19 4 A $0.00 $0 D/D 15,000 37,500     -
   Mccarthy Sean A. President and CEO   •       •      –    2022-07-19 4 A $0.00 $0 D/D 40,000 305,853     -
   Mccarthy Sean A. President and CEO   •       •      –    2022-05-09 4 OE $0.95 $85,930 D/D 90,931 265,853     -

  38 Records found
  1  2   
  Page 1 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed